Multicenter and all‐comers validation of a score to select patients for manual thrombectomy, the DDTA score

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P‐PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and m...

Full description

Saved in:

Bibliographic Details
Published in:	Catheterization and cardiovascular interventions Vol. 98; no. 3; pp. E342 - E350
Main Authors:	Cordero, Alberto, Cid‐Alvarez, Belén, Alegría, Eduardo, Fernández‐Cisnal, Agustín, Escribano, David, Bautista, Jenniffer, Juskova, Maria, Trillo, Ramiro, Bertomeu‐Gonzalez, Vicente, Ferreiro, José Luis
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 01-09-2021 Wiley Subscription Services, Inc
Subjects:	Implants Mortality Patients primary angioplasty STEMI thrombectomy STEMI thrombectomy primary angioplasty
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P‐PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P‐PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end‐point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no‐reflow incidence, in‐hospital mortality and in‐hospital major cardiovascular events (MACE). In‐hospital prognosis was assessed by the Zwolle risk score. Results Three hundred forty patients were included in the validation cohort and no differences were observed as compared to the design cohort (618 patients) except for lower use of MT and higher IIb/IIIa inhibitors or drug‐eluting stents. The probability of TIMI 3 after MT decreased as delay to P‐PCI was higher. If DDTA score, MT was associated to TIMI 3 after MT (OR: 4.11) and final TIMI 3 (OR: 2.44). There was a linear and continuous relationship between DDTA score and all endpoints. DDTA score ≥ 4 was independently associated to lower no‐reflow, in‐hospital MACE or mortality. The lowest incidence of in‐hospital mortality or MACE was in patients who had DDTA score ≥ 4 and Zwolle risk score 0–3. Conclusions MT is associated to higher rate of final TIMI3 in patients with the DDTA score ≥ 4. Patients with DDTA score ≥ 4 had lower no‐reflow and in‐hospital complications.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Undefined-2
ISSN:	1522-1946 1522-726X
DOI:	10.1002/ccd.29689